[exclusive] the tumor immunity is still hot. Look at the top 10 news events in 2018

Tumor immunity has always been the focus of the pharmaceutical industry In recent years, there have been many M & A cases with tumor immunity For example, in recent days, BMS and Lilly have acquired a series of tumor immunity drugs with great market potential through M & A In addition, at the ongoing JPM conference, tumor immunity is still hot In order to maintain sustainable innovation vitality or enrich the product line, companies of all sizes are busy looking for cooperation opportunities in this field in order not to fall behind in the era of tumor immunity In order to review the most concerned news events in the field of tumor immunity in 2018, Patricia recently wrote an article on the immuno oncology news website, reviewing the most concerned news event TOP10 in the field of tumor immunity in 2018 Through the review, we can not only see the difficulties along the way, but also see infinite "vitality" Top 10: a phase III clinical data of pegilodecakin shows that it is expected to treat advanced pancreatic cancer Pegilodecakin is a long-acting recombinant human interleukin-10 (IL-10) developed by armo Biosciences, which can indirectly block the production of cancer cytotoxin CD8 positive T cells In a clinical trial of 566 patients with advanced pancreatic cancer who received first-line chemotherapy, pegilodecakin (am0010) combined with FOLFOX chemotherapy showed safety to ensure that the study can continue Pegilodecakin has been approved by the US FDA and the European Commission as an orphan drug for the treatment of advanced pancreatic cancer, and pegilodecakin combined with FOLFOX chemotherapy as a second-line drug for the treatment of pancreatic cancer has entered the FDA fast channel One month after the announcement, Lilly announced a final agreement with ARMA biosciences to acquire ARMA for $50 per share and a total of $1.6 billion The acquisition will bring multiple candidate drugs (including pegilodecakin (am0010)) of armo to Lilly to strengthen its tumor immunity program Top9: car-t cell immunotherapy can kill advanced pancreatic cancer cells in mice After kymriah and yescarta were approved by FDA in 2017, car-t therapy has become a hot field In a study on human-induced advanced pancreatic cancer in mice, car-t cell immunotherapy can clear cancer cells in mice, including cancer cells that have been transferred to other tissues Traditional car-t cells proliferate in large numbers after identifying the target, which means that they may cause cytotoxicity Different from the traditional car-t cell therapy, the switch of car-t immune cells can be used as a bridge between the target and anti-cancer cells Using this switch can help them accurately target multiple areas of a single protein and solve the risk of potential cytotoxicity Top8: keytruda combined with epacadostat failed to reach the primary end point in a clinical phase III trial for melanoma In a phase III trial for patients with metastatic melanoma, keytruda combined with epacadostat failed to reach the primary end point and was stopped by Incyte and Merck This combination therapy has not been shown to be superior to keytruda alone in terms of overall survival Top 7: ASCO and NCCN release guidelines to help doctors recognize and manage the side effects of immunosuppressive agents Although immunosuppressive agents can restore the immune system's ability to attack and destroy tumor cells, there are also risks associated with this treatment, such as the possibility of attacking healthy cells of patients In order to help clinicians find side effects as early as possible and provide treatment as soon as possible, ASCO and NCCN issued guidelines on how to evaluate and deal with side effects caused by immunosuppressive checkpoint inhibitors Top.6: immunotherapy compound m7824, developed by emdserono, has been shown to be effective in phase I clinical trials of patients with advanced lung cancer In a phase I trial, 25% of patients showed a significant reduction in tumor size The drug has multiple mechanisms It can block the immunocheckpoint molecule PD-L1 and capture the immunosuppressive molecule TGF beta Top5: keytruda slows down the progression of liver cancer in a phase II clinical trial Although keytruda and epacadostat failed to reach the primary end point in a phase III clinical trial for melanoma, keytruda alone has good clinical efficacy in patients with advanced liver cancer In keynote-224, 61.5% of patients had stable disease, but only 1% had complete remission TOP4: the new opdivo dosage scheme allows patients to give drugs once every four weeks In early 2018, a new opdivo dosage scheme was approved by FDA for multiple tumors, which allows patients to give drugs once every four weeks Patients need to receive 240mg every time in the two-week plan, and only 480mg every four weeks in the new plan, which will greatly facilitate the daily life of patients Top3: research shows that cancer cells can fight against immune response by releasing small vesicles with PD-L1 in the blood circulation Cancer cells are not just a group of uncontrolled growth cells; they actively participate in the fight with the immune system for their own survival In addition to releasing the PD-L1 checkpoint protein to suppress the immune response, cancer cells also release vesicles called exosomes in the blood circulation, which carry the PD-L1 protein, which causes T cells to be exhausted before they reach the tumor and fight Although the study focused on metastatic melanoma, the researchers found that breast and lung cancer also release exosomes carrying PD-L1 Top2: FDA approved opdivo for advanced non-small cell lung cancer patients approved in 2018 for the treatment of metastatic non-small cell lung cancer patients who failed to receive platinum chemotherapy is definitely a major event in the history of tumor immunity In an I / II trial, 12% of the patients responded to the treatment of opdivo without considering the expression level of PD-L1, marking that it is the first new drug for the treatment in the past 20 years Top1: a phase III clinical trial showed that keytruda was superior to chemotherapy in improving the survival rate of non-small cell lung cancer patients A phase III trial named keynote-042 showed that keytruda significantly prolonged the life span of patients with locally advanced or metastatic non-small cell lung cancer compared with standard platinum chemotherapy These trials are the largest in tumor immunity, with more than 700 studies conducted in various cancers The drug is now on the market and has entered the Chinese market In a word, the road of tumor immunity in 2018 has been bumpy and breakthrough It is gratifying that not only keytruda and opdivo have been approved to be listed in China and their prices are far lower than the global market, but also tripril mAb and Sindal's sinrili mAb of Junshi biology have been approved to be listed in China at the end of 2018 It is reported that the price of trepril mAb of Junshi biology is about one third of that of drug K although the price has some adverse effects on other PD-1 products under development, it can greatly benefit the suffering patients I believe there will be more miracles in 2019 References: 1 Top 10 immune oncology stories of 2018 2 IO continues to be popular, big pharmaceutical companies invest heavily in buying: the real record statement of the conference: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.